Caroline Robert

157.6k total citations · 27 hit papers
650 papers, 41.8k citations indexed

About

Caroline Robert is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Caroline Robert has authored 650 papers receiving a total of 41.8k indexed citations (citations by other indexed papers that have themselves been cited), including 453 papers in Oncology, 315 papers in Molecular Biology and 139 papers in Immunology. Recurrent topics in Caroline Robert's work include Cancer Immunotherapy and Biomarkers (244 papers), Melanoma and MAPK Pathways (241 papers) and CAR-T cell therapy research (192 papers). Caroline Robert is often cited by papers focused on Cancer Immunotherapy and Biomarkers (244 papers), Melanoma and MAPK Pathways (241 papers) and CAR-T cell therapy research (192 papers). Caroline Robert collaborates with scholars based in France, United States and Germany. Caroline Robert's co-authors include James Larkin, Dirk Schadendorf, F. Stephen Hodi, Alexander M.M. Eggermont, Franck Carbonnel, Omid Hamid, Jedd D. Wolchok, John B.A.G. Haanen, Jeffrey S. Weber and Reinhard Dummer and has published in prestigious journals such as Nature, New England Journal of Medicine and Cell.

In The Last Decade

Caroline Robert

628 papers receiving 41.1k citations

Hit Papers

Management of toxicities from immuno... 2005 2026 2012 2019 2017 2015 2020 2012 2017 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    2017 1.7k citations Caroline Robert, James Larkin et al. profile →
  2. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
    2015 1.6k citations Dirk Schadendorf, F. Stephen Hodi et al. Journal of Clinical Oncology profile →
  3. A decade of immune-checkpoint inhibitors in cancer therapy
    2020 1.1k citations Caroline Robert Nature Communications profile →
  4. Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group
    2012 1.1k citations Keith T. Flaherty, Caroline Robert et al. profile →
  5. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab
    2017 972 citations Nathalie Chaput, Émilie Routier et al. profile →
  6. Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With Cancer
    2005 934 citations Caroline Robert et al. Journal of Clinical Oncology profile →
  7. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
    2017 898 citations Antoni Ribas, Georgina V. Long et al. profile →
  8. Removal of C.I. Basic Green 4 (Malachite Green) from aqueous solutions by adsorption using cyclodextrin-based adsorbent: Kinetic and equilibrium studies
    2006 892 citations Caroline Robert et al. profile →
  9. Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
    2017 874 citations Jeffrey S. Weber, F. Stephen Hodi et al. Journal of Clinical Oncology profile →
  10. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
    2016 813 citations Émilie Routier, Aurélien Marabelle et al. profile →
  11. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
    2019 768 citations Caroline Robert, Antoni Ribas et al. profile →
  12. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
    2019 703 citations Georgina V. Long, Reinhard Dummer et al. profile →
  13. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
    2018 675 citations Reinhard Dummer, Paolo A. Ascierto et al. profile →
  14. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
    2019 638 citations Omid Hamid, Caroline Robert et al. profile →
  15. Electrochemotherapy – An easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: Results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study
    2006 628 citations Caroline Robert et al. profile →
  16. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
    2022 565 citations Caroline Robert, James Larkin et al. profile →
  17. CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients
    2013 557 citations Patrick A. Ott, F. Stephen Hodi et al. Clinical Cancer Research profile →
  18. Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab
    2015 503 citations Lise Boussemart, Christine Mateus et al. profile →
  19. Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
    2017 482 citations Caroline Robert, Jean‐Jacques Grob et al. profile →
  20. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial
    2020 442 citations Caroline Robert, Piotr Rutkowski et al. profile →
  21. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial
    2018 392 citations Reinhard Dummer, Paolo A. Ascierto et al. profile →
  22. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors
    2018 376 citations Stéphane Champiat, Christine Mateus et al. profile →
  23. Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody
    2016 281 citations Neil H. Segal, Theodore F. Logan et al. Clinical Cancer Research profile →
  24. Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma
    2013 233 citations Jedd D. Wolchok, F. Stephen Hodi et al. profile →
  25. Tumour burden and efficacy of immune-checkpoint inhibitors
    2021 209 citations Aurélien Marabelle, Nathalie Chaput et al. profile →
  26. The multiple roles of LDH in cancer
    2022 173 citations Stéphan Vagner, Caroline Robert et al. profile →
  27. Tumor-associated high endothelial venules mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combination immunotherapy
    2022 162 citations Séverine Le Roy, Isabelle Girault et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Caroline Robert France 101 28.1k 15.4k 11.4k 6.6k 3.3k 650 41.8k
Michael B. Atkins United States 91 25.3k 0.9× 16.0k 1.0× 12.0k 1.0× 12.6k 1.9× 3.5k 1.1× 577 40.7k
Alexander M.M. Eggermont Netherlands 72 18.5k 0.7× 9.4k 0.6× 6.7k 0.6× 3.1k 0.5× 3.5k 1.1× 389 25.8k
Jedd D. Wolchok United States 119 45.3k 1.6× 16.2k 1.0× 29.7k 2.6× 11.0k 1.7× 3.3k 1.0× 568 65.0k
Richard Pazdur United States 106 19.8k 0.7× 10.6k 0.7× 3.7k 0.3× 10.3k 1.6× 1.9k 0.6× 596 37.7k
Daniel D. Von Hoff United States 91 23.6k 0.8× 19.7k 1.3× 2.8k 0.2× 6.7k 1.0× 4.1k 1.2× 821 44.9k
Martin Gore United Kingdom 78 14.4k 0.5× 12.9k 0.8× 3.6k 0.3× 9.0k 1.4× 1.7k 0.5× 382 29.5k
Charles M. Rudin United States 86 15.7k 0.6× 17.2k 1.1× 2.1k 0.2× 7.6k 1.1× 6.4k 2.0× 458 31.1k
Jennifer A. Wargo United States 68 15.9k 0.6× 11.4k 0.7× 8.2k 0.7× 3.6k 0.5× 1.5k 0.5× 263 25.5k
Jean‐Charles Soria France 95 19.7k 0.7× 13.0k 0.8× 4.7k 0.4× 12.8k 1.9× 1.5k 0.5× 679 34.8k
Lisa M. Coussens United States 81 27.4k 1.0× 23.6k 1.5× 21.6k 1.9× 6.3k 1.0× 2.9k 0.9× 198 61.3k

Countries citing papers authored by Caroline Robert

Since Specialization
Citations

This map shows the geographic impact of Caroline Robert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Caroline Robert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Caroline Robert more than expected).

Fields of papers citing papers by Caroline Robert

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Caroline Robert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Caroline Robert. The network helps show where Caroline Robert may publish in the future.

Co-authorship network of co-authors of Caroline Robert

This figure shows the co-authorship network connecting the top 25 collaborators of Caroline Robert. A scholar is included among the top collaborators of Caroline Robert based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Caroline Robert. Caroline Robert is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Schadendorf, Dirk, Jason J. Luke, Paolo A. Ascierto, et al.. (2024). Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial. Journal for ImmunoTherapy of Cancer. 12(3). e007501–e007501. 5 indexed citations
2.
Böhm, Markus, et al.. (2024). An overview of benefits and risks of chronic melanocortin‐1 receptor activation. Journal of the European Academy of Dermatology and Venereology. 39(1). 39–51. 5 indexed citations
3.
Yurchenko, Andrey A., Tirzah Braz Petta Lajus, Hiva Fassihi, et al.. (2023). Genomic mutation landscape of skin cancers from DNA repair-deficient xeroderma pigmentosum patients. Nature Communications. 14(1). 2561–2561. 28 indexed citations
4.
Sun, Roger, Marvin Lerousseau, Émilie Routier, et al.. (2022). Radiomics to evaluate interlesion heterogeneity and to predict lesion response and patient outcomes using a validated signature of CD8 cells in advanced melanoma patients treated with anti-PD1 immunotherapy. Journal for ImmunoTherapy of Cancer. 10(10). e004867–e004867. 21 indexed citations
5.
Robert, Caroline, Célèste Lebbé, Thierry Lesimple, et al.. (2022). Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1. Clinical Cancer Research. 29(5). 858–865. 15 indexed citations
6.
Long, Georgina V., Caroline Robert, Marcus O. Butler, et al.. (2021). Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules. Clinical Cancer Research. 27(19). 5280–5288. 24 indexed citations
7.
Schadendorf, Dirk, Caroline Robert, Reinhard Dummer, et al.. (2021). Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers. European Journal of Cancer. 153. 234–241. 16 indexed citations
8.
Tselikas, Lambros, Stéphane Champiat, Rahul A. Sheth, et al.. (2021). Interventional Radiology for Local Immunotherapy in Oncology. Clinical Cancer Research. 27(10). 2698–2705. 26 indexed citations
9.
Robert, Caroline, Antoni Ribas, Omid Hamid, et al.. (2017). Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma. Journal of Clinical Oncology. 36(17). 1668–1674. 336 indexed citations
10.
Boussemart, Lise, Isabelle Girault, Hélène Malka-Mahieu, et al.. (2016). Secondary Tumors Arising in Patients Undergoing BRAF Inhibitor Therapy Exhibit Increased BRAF–CRAF Heterodimerization. Cancer Research. 76(6). 1476–1484. 33 indexed citations
11.
Segal, Neil H., Theodore F. Logan, F. Stephen Hodi, et al.. (2016). Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody. Clinical Cancer Research. 23(8). 1929–1936. 281 indexed citations breakdown →
12.
Holderfield, Matthew, Edward Lorenzana, Ben Weisburd, et al.. (2014). Vemurafenib Cooperates with HPV to Promote Initiation of Cutaneous Tumors. Cancer Research. 74(8). 2238–2245. 20 indexed citations
13.
Bourillon, Agnès, Wei Yang, Caroline Pouvelle, et al.. (2013). Correlation of Phenotype/Genotype in a Cohort of 23 Xeroderma Pigmentosum-Variant Patients Reveals 12 New Disease-CausingPOLHMutations. Human Mutation. 35(1). 117–128. 28 indexed citations
14.
Ott, Patrick A., F. Stephen Hodi, & Caroline Robert. (2013). CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients. Clinical Cancer Research. 19(19). 5300–5309. 557 indexed citations breakdown →
15.
Eggermont, Alexander M.M., Stefan Suciu, Alessandro Testori, et al.. (2012). Long-Term Results of the Randomized Phase III Trial EORTC 18991 of Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma. Journal of Clinical Oncology. 30(31). 3810–3818. 190 indexed citations
16.
Kirkwood, John M., Lars Bastholt, Caroline Robert, et al.. (2011). Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma. Clinical Cancer Research. 18(2). 555–567. 218 indexed citations
17.
Oberholzer, Patrick A., Damien Kee, Piotr Dziunycz, et al.. (2011). RAS Mutations Are Associated With the Development of Cutaneous Squamous Cell Tumors in Patients Treated With RAF Inhibitors. Journal of Clinical Oncology. 30(3). 316–321. 298 indexed citations
18.
Viaud, Sophie, Caroline Flament, Mustapha Zoubir, et al.. (2010). Cyclophosphamide Induces Differentiation of Th17 Cells in Cancer Patients. Cancer Research. 71(3). 661–665. 136 indexed citations
19.
Robert, Caroline, et al.. (2007). [Epithelial and melanic skin tumours].. PubMed. 57(18). 2067–79. 3 indexed citations
20.
Bonvalot, Sylvie, D. Vanel, Philippe Terrier, et al.. (2004). Traitement des récidives des sarcomes rétro-péritonéaux. Bulletin du Cancer. 91(11). 845–852. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael B. Atkins Breakdown of academic impact, for papers by Alexander M.M. Eggermont Breakdown of academic impact, for papers by Jedd D. Wolchok Breakdown of academic impact, for papers by Richard Pazdur Breakdown of academic impact, for papers by Daniel D. Von Hoff Breakdown of academic impact, for papers by Martin Gore Breakdown of academic impact, for papers by Charles M. Rudin Breakdown of academic impact, for papers by Jennifer A. Wargo Breakdown of academic impact, for papers by Jean‐Charles Soria Breakdown of academic impact, for papers by Lisa M. Coussens
Rankless by CCL
2026